Development of targeted alpha particle therapy for solid tumors.

Geant4—a simulation toolkit

Agostinelli, S., Allison, J., Amako, K., Apostolakis, J., Araujo, H., Arce, P., Asai, M., Axen, D., Banerjee, S., Barrand, G., et al. (2003) · Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment · doi:10.1016/s0168-9002(03)01368-8 · Cited by 25,106 · see citing works

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works

Tumour heterogeneity and resistance to cancer therapies

Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846 · see citing works

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · see citing works

The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy

Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,228 · see citing works

Tumor heterogeneity: Causes and consequences

Marusyk, A., & Polyák, K. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.002 · Cited by 1,597 · see citing works

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340 · see citing works

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., & Pless, J. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90087-x · Cited by 1,332 · see citing works

The Chemistry of the Actinide and Transactinide Elements

Morss, L. R., Katz, J. J., Fuger, J., & Edelstein, N. M. (2006) · Springer eBooks · doi:10.1007/1-4020-3598-5 · Cited by 1,291 · see citing works

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,163 · see citing works

Computerized three‐dimensional segmented human anatomy

Zubal, I. G., Harrell, C. R., Smith, E. O., Rattner, Z., Gindi, G. R., & Hoffer, P. B. (1994) · Medical Physics · doi:10.1118/1.597290 · Cited by 1,105 · see citing works

The EGS4 Code System

Nelson, W. R., USDOE Office of Science (SC), Hirayama, H., & Rogers, D. W. O. (1985) · doi:10.2172/1453993 · Cited by 971 · see citing works

Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819 · see citing works

Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review

Maack, T., Johnson, V., Kau, S. T., Figueiredo, J. F., & Sigulem, D. (1979) · Kidney International · doi:10.1038/ki.1979.128 · Cited by 763 · see citing works

Recombinant adeno-associated virus for muscle directed gene therapy

Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654 · see citing works

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552 · see citing works

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505 · see citing works

Tumor therapy with targeted atomic nanogenerators.

McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501 · see citing works

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Sartor, O. A., Coleman, R., Nilsson, S. F., Heinrich, D. A., Helle, S. I., O’Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J. P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70183-4 · Cited by 497 · see citing works

Targeted α particle immunotherapy for myeloid leukemia

Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472 · see citing works

Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes

McDevitt, M. R., Chattopadhyay, D., Kappel, B. J., Jaggi, J. S., Schiffman, S. R., Antczak, C., Njardarson, J. T., Brentjens, R. J., & Scheinberg, D. A. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.039131 · Cited by 453 · see citing works

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

Nilsson, S. F., Larsen, R. H., Fosså, S. D., Balteskard, L., Borch, K. W., Westlin, J., Salberg, G., & Bruland, Ø. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2244 · Cited by 439 · see citing works

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control

Kratochwil, C., Bruchertseifer, F., Rathke, H. G., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 429 · see citing works

Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

Zalutsky, M. R., Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., McLendon, R. E., Wong, T. Z., & Bigner, D. D. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046938 · Cited by 414 · see citing works

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

Hoskin, P., Sartor, O. A., O’Sullivan, J. M., Johannessen, D. C., Helle, S. I., Logue, J. P., Bottomley, D., Nilsson, S. F., Vogelzang, N. J., Fang, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70474-7 · Cited by 409 · see citing works

213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R. A., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 406 · see citing works

Engineered antibodies

Hudson, P. J., & Souriau, C. (2003) · Nature Medicine · doi:10.1038/nm0103-129 · Cited by 397 · see citing works

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth

Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M. M., Królicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 371 · see citing works

225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

Sathekge, M. M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I. O., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 361 · see citing works

High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?

Bruland, Ø. S., Nilsson, S. F., Fisher, D. R., & Larsen, R. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0841 · Cited by 356 · see citing works

DPM, a fast, accurate Monte Carlo code optimized for photon and electron radiotherapy treatment planning dose calculations

Sempau, J., Wilderman, S. J., & Bielajew, A. F. (2000) · Physics in Medicine and Biology · doi:10.1088/0031-9155/45/8/315 · Cited by 323 · see citing works

Cerenkov Luminescence Imaging of Medical Isotopes

Ruggiero, A., Holland, J. P., Lewis, J. S., & Grimm, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076521 · Cited by 302 · see citing works

Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study

Andersson, H., Cederkrantz, E., Bäck, T. A., Divgi, C. R., Elgqvist, J., Himmelman, J., Horváth, G., Jacobsson, L., Jensen, H. J., Lindegren, S., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.062604 · Cited by 298 · see citing works

An Eighteen‐Membered Macrocyclic Ligand for Actinium‐225 Targeted Alpha Therapy

Thiele, N. A., Brown, V., Kelly, J. M., Amor‐Coarasa, A., Jermilova, U., MacMillan, S. N., Nikolopoulou, A., Ponnala, S., Ramogida, C. F., Robertson, A. K. H., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201709532 · Cited by 291 · see citing works

An overview of targeted alpha therapy

Kim, Y., & Brechbiel, M. W. (2011) · Tumor Biology · doi:10.1007/s13277-011-0286-y · Cited by 280 · see citing works

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

Rosenblat, T. L., McDevitt, M. R., Mulford, D. A., Pandit-Taskar, N. D., Divgi, C. R., Panageas, K. S., Heaney, M. L., Chanel, S. M., Morgenstern, A., Sgouros, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0382 · Cited by 272 · see citing works

An Ion-exchange Study of Possible Hybridized 5f Bonding in the Actinides1

Diamond, R. M., Street, K., & Seaborg, G. T. (1954) · Journal of the American Chemical Society · doi:10.1021/ja01635a001 · Cited by 264 · see citing works

MicroPET and Autoradiographic Imaging of Breast Cancer αv-Integrin Expression Using 18F- and 64Cu-Labeled RGD Peptide

Chen, X. S., Park, R. J.-H., Tohme, M. S., Shahinian, A. H., Bading, J. R., & Conti, P. S. (2003) · Bioconjugate Chemistry · doi:10.1021/bc0300403 · Cited by 260 · see citing works

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen, X. S., Hou, Y., Tohme, M. S., Park, R. J.-H., Khankaldyyan, V., Gonzales-Gomez, I., Bading, J. R., Laug, W. E., & Conti, P. S. (2004) · PubMed · Cited by 256 · see citing works

A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?

de Kruijff, R. M., Wolterbeek, H. T., & Denkova, A. G. (2015) · Pharmaceuticals · doi:10.3390/ph8020321 · Cited by 254 · see citing works

MIRD Pamphlet No. 17: The Dosimetry of Nonuniform Activity Distributions—Radionuclide S Values at the Voxel Level

Bolch, W. E., Bouchet, L. G., Robertson, J. S., Wessels, B. W., Siegel, J. A., Howell, R. W., Erdi, A. K., Aydogan, B., Costes, S. V., Watson, E. E., et al. (1999) · Cited by 253 · see citing works

Mutation and Inactivation of Cultured Mammalian Cells Exposed to Beams of Accelerated Heavy Ions

Thacker, J., Stretch, A., & Stephens, M. A. (1979) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553007914550891 · Cited by 251 · see citing works

Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.

Henriksen, G., Fisher, D. R., Roeske, J. C., Bruland, Ø. S., & Larsen, R. H. (2003) · PubMed · Cited by 250 · see citing works

Clinical radioimmunotherapy—the role of radiobiology

Pouget, J., Navarro‐Teulon, I., Bardiès, M., Chouin, N., Cartron, G., Pèlegrin, A., & Azria, D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.160 · Cited by 249 · see citing works

A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer

Nilsson, S. F., Strang, P. M., Aksnes, A., Franzén, L., Olivier, P., Pecking, A. P., Staffurth, J., Vasanthan, S., Andersson, C. K., & Bruland, Ø. S. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.023 · Cited by 245 · see citing works

MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee.

Bolch, W. E., Bouchet, L. G., Js, R., Wessels, B. W., Ja, S., Howell, R. W., Ak, E., Aydogan, B., Costes, S. V., Ee, W., et al. (1999) · PubMed · Cited by 237 · see citing works

Design and synthesis of 225Ac radioimmunopharmaceuticals.

McDevitt, M. R., Ma, D., Simon, J., Frank, R. K., & Scheinberg, D. A. (2002) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(02)00167-7 · Cited by 225 · see citing works

Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.

Pandit-Taskar, N. D., Batraki, M., & Divgi, C. R. (2004) · PubMed · Cited by 224 · see citing works

Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications

Miederer, M., Scheinberg, D. A., & McDevitt, M. R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.009 · Cited by 210 · see citing works

MicroPET imaging of breast cancer ?-integrin expression with Cu-labeled dimeric RGD peptides

Chen, X., Liu, S., Hou, Y., Tohme, M., PARK, R., Bading, J. R., & Conti, P. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.06.004 · Cited by 210 · see citing works

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Sgouros, G., Ballangrud, Å., Jurcic, J. G., McDevitt, M. R., Humm, J. L., Erdi, Y. E., Mehta, B. M., Finn, R. D., Larson, S. M., & Scheinberg, D. A. (1999) · PubMed · Cited by 207 · see citing works

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205 · see citing works

Astatine-211-Labeled Radiotherapeutics An Emerging Approach to Targeted Alpha-Particle Radiotherapy

Zalutsky, M. R., & Vaidyanathan, G. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003399275 · Cited by 203 · see citing works

Astatine-211: Production and Availability

Zalutsky, M. R., & Pruszyński, M. (2011) · Current Radiopharmaceuticals · doi:10.2174/1874471011104030177 · Cited by 200 · see citing works

Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225 Ac-PSMA-617 Radioligand Therapy

Sathekge, M. M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Reyneke, F., Maes, A., Kratochwil, C., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229229 · Cited by 196 · see citing works

The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond

Elgqvist, J., Frost, S. H. L., Pouget, J., & Albertsson, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2013.00324 · Cited by 194 · see citing works

Bone-seeking radionuclides for therapy.

Lewington, V. J. (2005) · PubMed · Cited by 191 · see citing works

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies

Crawford, E. D., Higano, C. S., Shore, N. D., Hussain, M., & Petrylak, D. P. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.06.106 · Cited by 190 · see citing works

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

Nilsson, S. F., Cislo, P. R., Sartor, O. A., Vogelzang, N. J., Coleman, R. E., O’Sullivan, J. M., Reuning-Scherer, J. D., Shan, M., Zhan, L., & Parker, C. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw065 · Cited by 184 · see citing works

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Nikula, T. K., McDevitt, M. R., Finn, R. D., Wu, C., Kozak, R. W., Garmestani, K., Brechbiel, M. W., Curcio, M. J., Pippin, C. G., Tiffany-Jones, L., et al. (1999) · PubMed · Cited by 176 · see citing works

Actinium-225 in targeted alpha-particle therapeutic applications.

A. Scheinberg, D., & R. McDevitt, M. (2011) · Current Radiopharmaceuticalse · doi:10.2174/1874471011104040306 · Cited by 176 · see citing works

General aspects of the cellular response to low- and high-LET radiation

Pouget, J., & Mather, S. J. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100484 · Cited by 172 · see citing works

Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes

McDevitt, M. R., McDevitt, M. R., Ruggiero, A., Villa, C. H., Holland, J. P., Sprinkle, S. R., May, C., Lewis, J. S., & Scheinberg, D. A. (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s13300 · Cited by 171 · see citing works

Cancer radioimmunotherapy with alpha-emitting nuclides

Couturier, O., Supiot, S., Mougin‐Degraef, M., Faivre-Chauvet, A., Carlier, T., Chatal, J., Davodeau, F., & Chérel, M. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1803-2 · Cited by 169 · see citing works

A Systematic Overview of Radiation Therapy Effects in Skeletal Metastases

Falkmer, S., Järhult, J., Wersäll, P. J., & Cavallin-Ståhl, E. K. (2003) · Acta Oncologica · doi:10.1080/02841860310014895 · Cited by 167 · see citing works

Mutation and Inactivation of Cultured Mammalian Cells Exposed to Beams of Accelerated Heavy Ions IV. Biophysical Interpretation

GOODHEAD, D. T., Munson, R. J., Thacker, J., & Cox, R. (1980) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553008014550201 · Cited by 166 · see citing works

Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb

Chappell, L. L., Dadachova, E., Milenic, D. E., Garmestani, K., Wu, C., & Brechbiel, M. W. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(99)00086-4 · Cited by 160 · see citing works

Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y

Hong, S., Hobbs, R. F., Vajravelu, R. K., Huso, D. L., Esaias, C. E., Apostolidis, C., Morgenstern, A., & Sgouros, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1828 · Cited by 158 · see citing works

Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors

Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., & Essler, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4647 · Cited by 155 · see citing works

The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-***

Mirzadeh, S., Kumar, K., & Gansow, O. A. (1993) · Radiochimica Acta · doi:10.1524/ract.1993.60.1.1 · Cited by 155 · see citing works

Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P

Kneifel, S., Cordier, D., Good, S., Ionescu, M.-C. S., Ghaffari, A., Höfer, S., Kretzschmar, M., Tolnay, M., Apostolidis, C., Waser, B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2820 · Cited by 153 · see citing works

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

Borchardt, P. E., Yuan, R., Miederer, M., McDevitt, M. R., & Scheinberg, D. A. (2003) · PubMed · Cited by 150 · see citing works

Alpha-particles for targeted therapy

Sgouros, G. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.007 · Cited by 147 · see citing works

Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry

Prideaux, A. R., Song, H., Hobbs, R. F., He, B., Frey, E. C., Ladenson, P. W., Wahl, R. L., & Sgouros, G. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038000 · Cited by 145 · see citing works

Artificially Radioactive Element 85

Corson, D. R., MacKenzie, K. R., & Segre, E. (1940) · Physical Review · doi:10.1103/physrev.58.672 · Cited by 137 · see citing works

Pharmacokinetics and Imaging of 212 Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients

Meredith, R. F., Torgue, J. J.-C., Azure, M. T., Shen, S., Saddekni, S., Banaga, E., Carlise, R., Bunch, P., Yoder, D., & Alvarez, R. D. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1531 · Cited by 136 · see citing works

Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab

Meredith, R. F., Torgue, J. J.-C., Shen, S., Fisher, D. R., Banaga, E., Bunch, P., Morgan, D. E., Fan, J., & Straughn, J. M. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.143842 · Cited by 136 · see citing works

Melanoma Therapy via Peptide-Targeted α-Radiation

Miao, Y., Hylarides, M. D., Fisher, D. R., Shelton, T. D., Moore, H. A., WESTER, D. W., Fritzberg, A. R., Winkelmann, C. T., Hoffman, T. J., & Quinn, T. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0619 · Cited by 136 · see citing works

The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells

Jourdan, M., Ferlin, M., Legouffe, É., Horváthová, M., Liautard, J., Rossi, J. F., Wijdenes, J., Brochier, J., & Klein, B. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00623.x · Cited by 134 · see citing works

The Development of the α-Particle Emitting Radionuclides 212Bi and 213Bi, and Their Decay Chain Related Radionuclides, for Therapeutic Applications

Hassfjell, S. P., & Brechbiel, M. W. (2001) · Chemical Reviews · doi:10.1021/cr000118y · Cited by 133 · see citing works

Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Wild, D., Frischknecht, M., Zhang, H., Morgenstern, A., Bruchertseifer, F., Boisclair, J., Provencher-Bolliger, A., Reubi, J., & Maëcke, H. R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1186 · Cited by 132 · see citing works

Production of [ 211 At]-Astatinated Radiopharmaceuticals and Applications in Targeted α-Particle Therapy

Guérard, F., Gestin, J., & Brechbiel, M. W. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1292 · Cited by 131 · see citing works

The α-Camera: A Quantitative Digital Autoradiography Technique Using a Charge-Coupled Device for Ex Vivo High-Resolution Bioimaging of α-Particles

Bäck, T. A., & Jacobsson, L. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077578 · Cited by 131 · see citing works

Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodies

Zalutsky, M. R., Reardon, D. A., Pozzi, O. R., Vaidyanathan, G., & Bigner, D. D. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.03.007 · Cited by 130 · see citing works

Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 1: Cysteine Residues and Glycans

Adumeau, P., Sharma, S. K., Brent, C., & Zeglis, B. M. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0919-4 · Cited by 129 · see citing works

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Behr, T. M., Béhé, M. P., Stabin, M. G., Wehrmann, E., Apostolidis, C., Molinet, R., Strutz, F., Fayyazi, A., Wieland, E., Gratz, S., et al. (1999) · PubMed · Cited by 127 · see citing works

Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody

Schwartz, J., Jaggi, J. S., O’Donoghue, J. A., Ruan, S., McDevitt, M. R., Larson, S. M., Scheinberg, D. A., & Humm, J. L. (2011) · Physics in Medicine and Biology · doi:10.1088/0031-9155/56/3/012 · Cited by 126 · see citing works

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer

D’Huyvetter, M., Xavier, C., Caveliers, V., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.941803 · Cited by 124 · see citing works

Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy

McLaughlin, M. F., Woodward, J. D., Boll, R. A., Wall, J. S., Rondinone, A. J., Kennel, S. J., Mirzadeh, S., & Robertson, J. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054531 · Cited by 123 · see citing works

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Miederer, M., McDevitt, M. R., Sgouros, G., Kramer, K., Cheung, N. V., & Scheinberg, D. A. (2004) · PubMed · Cited by 119 · see citing works

Engineered liposomes for potential alpha-particle therapy of metastatic cancer.

Sofou, S., Thomas, J. L., Lin, H. Y., McDevitt, M. R., Scheinberg, D. A., & Sgouros, G. (2004) · PubMed · Cited by 119 · see citing works

Cerenkov imaging - a new modality for molecular imaging.

Thorek, D. L. J., Robertson, R., Bacchus, W. A., Hahn, J., Rothberg, J., Beattie, B. J., & Grimm, J. (2012) · Europe PMC (PubMed Central) · Cited by 118 · see citing works

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

Nilsson, S. F., Franzén, L., Parker, C. C., Tyrrell, C., Blom, R., Tennvall, J., Lennernäs, B., Petersson, U., Johannessen, D. C., Sokal, M., et al. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.07.002 · Cited by 118 · see citing works

Mutation and Inactivation of Cultured Mammalian Cells Exposed to Beams of Accelerated Heavy Ions

Cox, R., & Masson, W. K. (1979) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553007914550901 · Cited by 118 · see citing works

Large scale accelerator production of 225Ac: Effective cross sections for 78–192 MeV protons incident on 232Th targets

Griswold, J. R., Medvedev, D., Engle, J. W., Copping, R., Fitzsimmons, J., Radchenko, V., Cooley, J. C., Fassbender, M. E., Denton, D. L., Murphy, K. E., et al. (2016) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2016.09.026 · Cited by 116 · see citing works

Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease

Harrison, M. R., George, D. J., Wong, & Armstrong, A. J. (2013) · Cancer Management and Research · doi:10.2147/cmar.s25537 · Cited by 114 · see citing works

Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry.

Yoriyaz, H., Stabin, M. G., & dos Santos, A. (2001) · PubMed · Cited by 113 · see citing works

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.

McDevitt, M. R., Finn, R. D., Ma, D., Larson, S. M., & Scheinberg, D. A. (1999) · PubMed · Cited by 112 · see citing works

LaPO4 Nanoparticles Doped with Actinium-225 that Partially Sequester Daughter Radionuclides

Woodward, J. D., Kennel, S. J., Stuckey, A. C., Osborne, D., Wall, J. S., Rondinone, A. J., Standaert, R. F., & Mirzadeh, S. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100574f · Cited by 111 · see citing works

Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery

Mulvey, J. J., Villa, C. H., McDevitt, M. R., Escorcia, F. E., Casey, E. R., & Scheinberg, D. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.190 · Cited by 110 · see citing works

Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma

Raja, C., Graham, P., Rizvi, S. M., Song, E. Y., Goldsmith, H., Thompson, J. F., Bosserhoff, A., Morgenstern, A., Apostolidis, C., Kearsley, J. H., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.6.4089 · Cited by 110 · see citing works

Criteria for the Applicability of LET

Kellerer, A. M., & Chmelevsky, D. (1975) · Radiation Research · doi:10.2307/3574148 · Cited by 109 · see citing works

Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma

Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Królicki, B., Jakuciński, M., Pawlak, D., Apostolidis, C., Mirzadeh, S., Rola, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4225-7 · Cited by 109 · see citing works

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue

Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Królicki, B., Jakuciński, M., Pawlak, D., Apostolidis, C., Mirzadeh, S., Rola, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4015-2 · Cited by 108 · see citing works

Comparison of 225actinium chelates: tissue distribution and radiotoxicity

Davis, I. A., Glowienka, K. A., Boll, R. A., Deal, K. A., Brechbiel, M. W., Stabin, M. G., Bochsler, P. N., Mirzadeh, S., & Kennel, S. J. (1999) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(99)00024-4 · Cited by 105 · see citing works

Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids

Ballangrud, Å., Yang, W.-H., Palm, S., Enmon, R. M., Borchardt, P. E., Pellegrini, V., McDevitt, M. R., Scheinberg, D. A., & Sgouros, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0800 · Cited by 105 · see citing works

Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma

Poty, S., Carter, L. M., Mandleywala, K., Membreno, R., Abdel-Atti, D., Ragupathi, A., Scholz, W. W., Zeglis, B. M., & Lewis, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1650 · Cited by 105 · see citing works

213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model

Norenberg, J. P., Krenning, B. J., Konings, I. R. H. M., Kusewitt, D. F., Nayak, T. K., Anderson, T. L., de Jong, M., Garmestani, K., Brechbiel, M. W., & Kvols, L. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1264 · Cited by 104 · see citing works

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213

Zhang, M., Yao, Z., Garmestani, K., Axworthy, D. B., Zhang, Z., Mallett, R. W., Theodore, L. J., Goldman, C. K., Brechbiel, M. W., Carrasquillo, J. A., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0107 · Cited by 103 · see citing works

The iQID camera: An ionizing-radiation quantum imaging detector

Miller, B. W., Gregory, S., Fuller, E. S., Barrett, H. H., Barber, H. B., & Furenlid, L. R. (2014) · Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment · doi:10.1016/j.nima.2014.05.070 · Cited by 99 · see citing works

α-Particle Radioimmunotherapy of Disseminated Peritoneal Disease Using a 212 Pb-Labeled Radioimmunoconjugate Targeting HER2

Milenic, D. E., Garmestani, K., Brady, E. D., Albert, P. S., Ma, D., Abdulla, A., & Brechbiel, M. W. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.557 · Cited by 99 · see citing works

Efforts to Control the Errant Products of a Targeted <i>In vivo</i> Generator

Singh Jaggi, J., Kappel, B. J., McDevitt, M. R., Sgouros, G., Flombaum, C. D., Cabassa, C., & Scheinberg, D. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3096 · Cited by 98 · see citing works

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease

Coleman, R. E., Aksnes, A.-K., Naume, B., Garcia, C. A., Jérusalem, G., Piccart, M. J., Vobecky, N., Thuresson, M., & Flamen, P. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2939-1 · Cited by 97 · see citing works

Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome Carriers

Sofou, S., Kappel, B. J., Jaggi, J. S., McDevitt, M. R., Scheinberg, D. A., & Sgouros, G. (2007) · Bioconjugate Chemistry · doi:10.1021/bc070075t · Cited by 94 · see citing works

Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model

Ohshima, Y., Sudo, H., Watanabe, S., Nagatsu, K., Tsuji, A. B., Sakashita, T., Ito, Y. M., Yoshinaga, K., Higashi, T., & Ishioka, N. S. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3919-6 · Cited by 94 · see citing works

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

Sabet, A., Ezziddin, K., Pape, U., Reichman, K., Haslerud, T. M., Ahmadzadehfar, H., Biersack, H., Nagarajah, J., & Ezziddin, S. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2601-x · Cited by 93 · see citing works

Analysis of Patient Survival in a Phase I Trial of Systemic Targeted α-Therapy for Metastatic Melanoma

Allen, B., Singla, A. A., Rizvi, S. M. A., Graham, P., Bruchertseifer, F., Apostolidis, C., & Morgenstern, A. (2011) · Immunotherapy · doi:10.2217/imt.11.97 · Cited by 93 · see citing works

Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT

Rathke, H. G., Kratochwil, C., Hohenberger, R., Giesel, F. L., Bruchertseifer, F., Flechsig, P., Morgenstern, A., Hein, M., Plinkert, P. K., Haberkorn, U., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4135-8 · Cited by 93 · see citing works

Advancements in cancer therapy with alpha-emitters: a review

Imam, S. K. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01585-1 · Cited by 92 · see citing works

Three-Dimensional Imaging-Based Radiobiological Dosimetry

Sgouros, G., Frey, E. C., Wahl, R. L., He, B., Prideaux, A. R., & Hobbs, R. F. (2008) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.05.008 · Cited by 92 · see citing works

Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for α-Particle Radioimmunotherapy of Cancer

Maguire, W. F., McDevitt, M. R., Smith-Jones, P. M., & Scheinberg, D. A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138347 · Cited by 91 · see citing works

Optimizing Cancer Treatments to Induce an Acute Immune Response: Radiation Abscopal Effects, PAMPs, and DAMPs

Ludgate, C. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1175 · Cited by 91 · see citing works

Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin

Demartis, S., Tarli, L., Borsi, L., Zardi, L., & Neri, D. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100480 · Cited by 90 · see citing works

Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation

Malamas, A. S., Gameiro, S. R., Knudson, K. M., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.13520 · Cited by 90 · see citing works

Renal Tubulointerstitial Changes after Internal Irradiation with α-Particle–Emitting Actinium Daughters

Jaggi, J. S., Seshan, S. V., McDevitt, M. R., LaPerle, K., Sgouros, G., & Scheinberg, D. A. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110945 · Cited by 89 · see citing works

IL13RA2 targeted alpha particle therapy against glioblastomas

Sattiraju, A., Sai, K. K. S., Xuan, A., Pandya, D. N., Almaguel, F. G., Wadas, T. J., Herpai, D., Debinski, W., & Mintz, A. (2017) · Oncotarget · doi:10.18632/oncotarget.17792 · Cited by 89 · see citing works

Radiolytic footprinting. .beta. Rays, .gamma. photons, and fast neutrons probe DNA-protein interactions

Franchet-Beuzit, J., Spotheim-Maurizot, M., Sabattier, R., Blazy, B., & Charlier, M. (1993) · Biochemistry · doi:10.1021/bi00059a031 · Cited by 87 · see citing works

Quantitative Modeling of Cerenkov Light Production Efficiency from Medical Radionuclides

Beattie, B. J., Thorek, D. L. J., Schmidtlein, C. R., Pentlow, K. S., Humm, J. L., & Hielscher, A. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031402 · Cited by 87 · see citing works

A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model

Kelly, J. M., Amor‐Coarasa, A., Ponnala, S., Nikolopoulou, A., Williams, C. M., Thiele, N. A., Schlyer, D. J., Wilson, J. J., DiMagno, S. G., & Babich, J. W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219592 · Cited by 87 · see citing works

Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.

Huneke, R. B., Pippin, C. G., Squire, R. A., Brechbiel, M. W., Gansow, O. A., & Strand, M. (1992) · PubMed · Cited by 86 · see citing works

Production of 225Ac and 223Ra by irradiation of Th with accelerated protons

Zhuikov, B. L., Kalmykov, S. N., Ermolaev, S. V., Алиев, Р. А., Kokhanyuk, V. M., Matushko, V. L., Tananaev, I. G., & Myasoedov, B. F. (2011) · Radiochemistry · doi:10.1134/s1066362211010103 · Cited by 85 · see citing works

Coordination Chemistry with f-Element Complexes for an Improved Understanding of Factors That Contribute to Extraction Selectivity

Gorden, A. E. V., DeVore, M. A., & Maynard, B. A. (2012) · Inorganic Chemistry · doi:10.1021/ic300887p · Cited by 83 · see citing works

Synthesis, Conjugation, and Radiolabeling of a Novel Bifunctional Chelating Agent for 225Ac Radioimmunotherapy Applications

Chappell, L. L., Deal, K. A., Dadachova, E., & Brechbiel, M. W. (2000) · Bioconjugate Chemistry · doi:10.1021/bc990153f · Cited by 82 · see citing works

213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma

Chérel, M., Gouard, S., Gaschet, J., Maurel, C., Bruchertseifer, F., Morgenstern, A., Bourgeois, M., Gestin, J., Kraeber‐Bodéré, F., Barbet, J., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111997 · Cited by 81 · see citing works

Targeted radionuclide therapy

Williams, L. E., DeNardo, G. L., & Meredith, R. F. (2008) · Medical Physics · doi:10.1118/1.2938520 · Cited by 80 · see citing works

Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 2: Peptide Tags and Unnatural Amino Acids

Adumeau, P., Sharma, S. K., Brent, C., & Zeglis, B. M. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0920-y · Cited by 80 · see citing works

B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models

Kasten, B. B., Arend, R. C., Katre, A. A., Kim, H., Fan, J., Ferrone, S., Zinn, K. R., & Buchsbaum, D. J. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.01.003 · Cited by 80 · see citing works

Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.

Zalutsky, M. R., McLendon, R. E., Garg, P., Archer, G. E., Schuster, J. M., & Bigner, D. D. (1994) · PubMed · Cited by 79 · see citing works

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial

Parker, C. C., Finkelstein, S. E., Michalski, J. M., O’Sullivan, J. M., Bruland, Ø. S., Vogelzang, N. J., Coleman, R. E., Nilsson, S. F., Sartor, O. A., Li, R., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.002 · Cited by 77 · see citing works

Therapeutic Efficacy of Astatine-211–Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice

Palm, S., Bäck, T. A., Claesson, I., Danielsson, A., Elgqvist, J., Frost, S. H. L., Hultborn, R., Jensen, H. J., Lindegren, S., & Jacobsson, L. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.023 · Cited by 76 · see citing works

Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease

Milenic, D. E., Garmestani, K., Brady, E. D., Albert, P. S., Abdulla, A., Flynn, J. M., & Brechbiel, M. W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2300 · Cited by 76 · see citing works

Preliminary Therapy Evaluation of 225Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization

Pandya, D. N., Hantgan, R. R., Budzevich, M. M., Kock, N. D., Morse, D. L., Batista, I., Mintz, A., Li, K. C., & Wadas, T. J. (2016) · Theranostics · doi:10.7150/thno.14338 · Cited by 76 · see citing works

Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis

Essler, M., Gärtner, F. C., Neff, F., Blechert, B., Senekowitsch–Schmidtke, R., Bruchertseifer, F., Morgenstern, A., & Seidl, C. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2023-6 · Cited by 75 · see citing works

Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors

Escorcia, F. E., Henke, E., McDevitt, M. R., Villa, C. H., Smith-Jones, P. M., Blasberg, R. G., Benezra, R., & Scheinberg, D. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2029 · Cited by 75 · see citing works

Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model

Orozco, J. J., Bäck, T. A., Kenoyer, A. L., Balkin, E. R., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., Frayo, S. L., Hylarides, M. D., Green, D. J., et al. (2013) · Blood · doi:10.1182/blood-2012-11-467035 · Cited by 74 · see citing works

Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study

Autenrieth, M. E., Seidl, C., Bruchertseifer, F., Horn, T. D., Kurtz, F., Feuerecker, B., D’Alessandria, C., Pfob, C. H., Nekolla, S. G., Apostolidis, C., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4003-6 · Cited by 74 · see citing works

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Park, S. I., Shenoi, J., Pagel, J. M., Hamlin, D. K., Wilbur, D. S., Orgun, N. N., Kenoyer, A. L., Frayo, S. L., Axtman, A., Bäck, T. A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282327 · Cited by 73 · see citing works

Enhanced Loading Efficiency and Retention of225Ac in Rigid Liposomes for Potential Targeted Therapy of Micrometastases

Chang, M.-Y., Seideman, J. H., & Sofou, S. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700440a · Cited by 73 · see citing works

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

Elgqvist, J., Andersson, H., Bäck, T. A., Hultborn, R., Jensen, H. J., Karlsson, B., Lindegren, S., Palm, S., Warnhammar, E., & Jacobsson, L. (2005) · PubMed · Cited by 72 · see citing works

Methodology for labeling proteins and peptides with lead-212 (212Pb)

Baidoo, K. E., Milenic, D. E., & Brechbiel, M. W. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.01.010 · Cited by 71 · see citing works

Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb

Boudousq, V., Bobyk, L., Busson, M., Garambois, V., Jarlier, M., Charalambatou, P., Pèlegrin, A., Paillas, S., Chouin, N., Quénet, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069613 · Cited by 71 · see citing works

Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform

Besemer, A. E., Yang, Y. M., Grudzinski, J. J., Hall, L. T., & Bednarz, B. P. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2451 · Cited by 71 · see citing works

Radiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate Cancer

Dauer, L. T., Williamson, M. J., Humm, J. L., O’Donoghue, J. A., Ghani, R., Awadallah, R., Carrasquillo, J. A., Pandit-Taskar, N. D., Aksnes, A.-K., Biggin, C., et al. (2014) · Health Physics · doi:10.1097/hp.0b013e3182a82b37 · Cited by 70 · see citing works

Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.

Hartmann, F., Horak, E. M., Garmestani, K., Wu, C., Brechbiel, M. W., Kozak, R. W., Tso, J. Y., Kosteiny, S. A., Gansow, O. A., & Nelson, D. L. (1994) · PubMed · Cited by 69 · see citing works

Cerenkov Imaging

Das, S., Thorek, D. L. J., & Grimm, J. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-411638-2.00006-9 · Cited by 69 · see citing works

Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation

Yong, K. J., & Brechbiel, M. W. (2015) · AIMS Medical Science · doi:10.3934/medsci.2015.3.228 · Cited by 68 · see citing works

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model

Green, D. J., Shadman, M. S., Jones, J. C., Frayo, S. L., Kenoyer, A. L., Hylarides, M. D., Hamlin, D. K., Wilbur, D. S., Balkin, E. R., Lin, Y., et al. (2015) · Blood · doi:10.1182/blood-2014-11-612770 · Cited by 68 · see citing works

Development and validation of RAYDOSE: a Geant4-based application for molecular radiotherapy

Marcatili, S., Pettinato, C., Daniels, S., Lewis, D. G., Edwards, P., Fanti, S., & Spezi, E. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/8/2491 · Cited by 66 · see citing works

Molecular Targeted α-Particle Therapy for Oncologic Applications

Wadas, T. J., Pandya, D. N., Sai, K. K. S., & Mintz, A. (2014) · American Journal of Roentgenology · doi:10.2214/ajr.14.12554 · Cited by 65 · see citing works

Reduction of Kidney Uptake in Radiometal Labeled Peptide Linkers Conjugated to Recombinant Antibody Fragments. Site-Specific Conjugation of DOTA-Peptides to a Cys-Diabody

Li, L., Olafsen, T., Anderson, A.-L., Wu, A. M., Raubitschek, A. A., & Shively, J. E. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025565u · Cited by 64 · see citing works

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model

Fichou, N., Gouard, S., Maurel, C., Barbet, J., Ferrer, L., Morgenstern, A., Bruchertseifer, F., Faivre-Chauvet, A., Bigot‐Corbel, E., Davodeau, F., et al. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00076 · Cited by 64 · see citing works

203Pb-Labeled α-Melanocyte–Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection

Miao, Y., Figueroa, S. D., Fisher, D. R., Moore, H. A., Testa, R., Hoffman, T. J., & Quinn, T. P. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048553 · Cited by 63 · see citing works

Intravesical α-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice

Pfost, B., Seidl, C., Autenrieth, M. E., Saur, D., Bruchertseifer, F., Morgenstern, A., Schwaiger, M., & Senekowitsch–Schmidtke, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.065961 · Cited by 63 · see citing works

212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models

Kasten, B. B., Gangrade, A., Kim, H., Fan, J., Ferrone, S., Ferrone, C. R., Zinn, K. R., & Buchsbaum, D. J. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.12.004 · Cited by 62 · see citing works

Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator

Su, F., Beaumier, P. L., Axworthy, D. B., Atcher, R. W., & Fritzberg, A. R. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.06.009 · Cited by 61 · see citing works

Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid for radiolabeling proteins

Chappell, L. L., Ma, D., Milenic, D. E., Garmestani, K., Venditto, V. J., Beitzel, M., & Brechbiel, M. W. (2003) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(03)00033-7 · Cited by 60 · see citing works

Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the α-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies

Robinson, M. K., Shaller, C. C., Garmestani, K., Plascjak, P. S., Hodge, K. M., Yuan, Q., Marks, J. D., Waldmann, T. A., Brechbiel, M. W., & Adams, G. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1250 · Cited by 59 · see citing works

Targeted alpha therapy with 213Bi.

Morgenstern, A., Bruchertseifer, F., & Apostolidis, C. (2011) · Current Radiopharmaceuticalse · doi:10.2174/1874471011104040295 · Cited by 58 · see citing works

Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab

Abbas, N., Heyerdahl, H., Bruland, Ø. S., Borrebæk, J., Nesland, J., & Dahle, J. (2011) · EJNMMI Research · doi:10.1186/2191-219x-1-18 · Cited by 58 · see citing works

Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211

Nakamae, H., Wilbur, D. S., Hamlin, D. K., Thakar, M. S., Santos, E. B., Fisher, D. R., Kenoyer, A. L., Pagel, J. M., Press, O. W., Storb, R. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4363 · Cited by 57 · see citing works

Radiation-Induced Bystander Effects: Evidence for an Adaptive Response to Low Dose Exposures?

Mothersill, C. E., & Seymour, C. B. (2006) · Dose-Response · doi:10.2203/dose-response.06-111.mothersill · Cited by 57 · see citing works

Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor Cells

Drecoll, E., Gaertner, F. C., Miederer, M., Blechert, B., Vallon, M., Müller, J. M., Alke, A., Seidl, C., Bruchertseifer, F., Morgenstern, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005715 · Cited by 57 · see citing works

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

Morris, M. J., Loriot, Y., Sweeney, C. J., Fizazi, K. S., Ryan, C. J., Shevrin, D. H., Antonarakis, E. S., Pandit-Taskar, N. D., Deandreis, D., Jacene, H. A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.007 · Cited by 57 · see citing works

Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.

Andersson, H., Lindegren, S., Bäck, T. A., Jacobsson, L., Leser, G., & Horváth, G. (2000) · PubMed · Cited by 56 · see citing works

Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides

Wilbur, D. S. (2011) · Current Radiopharmaceuticals · doi:10.2174/1874471011104030214 · Cited by 55 · see citing works

Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues

Li, X., Patterson, J. T., Sarkar, M., Pedzisa, L., Kodadek, T. J., Roush, W. R., & Rader, C. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00244 · Cited by 55 · see citing works

Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of α-Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2

Miederer, M., McDevitt, M. R., Borchardt, P. E., Bergman, I., Kramer, K., Cheung, N. V., & Scheinberg, D. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0859 · Cited by 54 · see citing works

The inverse electron-demand Diels–Alder reaction as a new methodology for the synthesis of 225 Ac-labelled radioimmunoconjugates

Poty, S., Membreno, R., Glaser, J. M., Ragupathi, A., Scholz, W. W., Zeglis, B. M., & Lewis, J. S. (2018) · Chemical Communications · doi:10.1039/c7cc09129j · Cited by 54 · see citing works

Prospective carriers of 223Ra for targeted alpha particle therapy

Kozempel, J., Vlk, M., Málková, E., Bajzíková, A., Bárta, J., Santos‐Oliveira, R., & Rossi, A. M. (2014) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-014-3615-y · Cited by 53 · see citing works

Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugate

Zalutsky, M. R., Stabin, M. G., Larsen, R. H., & Bigner, D. D. (1997) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(97)00060-7 · Cited by 53 · see citing works

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Jurcic, J. G., Levy, M. Y., Park, J. H., Ravandi, F., Perl, A. E., Pagel, J. M., Smith, B. D., Estey, E. H., Kantarjian, H., Cicic, D., et al. (2016) · Blood · doi:10.1182/blood.v128.22.4050.4050 · Cited by 53 · see citing works

Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223

Anderson, P. M., Subbiah, V., & ROHREN, E. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_16 · Cited by 52 · see citing works

Dosage and response in radiopharmaceutical therapy of painful osseous metastases.

Silberstein, E. B. (1996) · PubMed · Cited by 52 · see citing works

Targeted α-Particle Therapy of Bone Metastases in Prostate Cancer

Jadvar, H., & Quinn, D. I. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000290 · Cited by 52 · see citing works

Improved efficacy of α‐particle–targeted radiation therapy

Milenic, D. E., Brady, E. D., Garmestani, K., Albert, P. S., Abdulla, A., & Brechbiel, M. W. (2010) · Cancer · doi:10.1002/cncr.24793 · Cited by 52 · see citing works

Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate inin vitroandin vivomodels of renal cell carcinoma

Hagemann, U. B., Mihaylova, D., Uran, S. R., Borrebaek, J., Grant, D., Bjerke, R. M., Karlsson, J., & Cuthbertson, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16910 · Cited by 52 · see citing works

Melanocortin 1 Receptor–Targeted α-Particle Therapy for Metastatic Uveal Melanoma

Tafreshi, N. K., Tichacek, C. J., Pandya, D. N., Doligalski, M. L., Budzevich, M. M., Kil, H., Bhatt, N., Kock, N. D., Messina, J. L., Ruiz, E., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217240 · Cited by 52 · see citing works

EANM’15

Pupillo, G., Boschi, A., Martini, P., Uccelli, L., Pasquali, M., Duatti, A., Domenico, G. D., Giganti, M., Taibi, A., Gambaccini, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3198-z · Cited by 52 · see citing works

The Radiochemical and Radiopharmaceutical Applications of Radium

Gott, M., Steinbach, J., & Mamat, C. (2016) · Open Chemistry · doi:10.1515/chem-2016-0011 · Cited by 51 · see citing works

Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.

Andersson, H., Elgqvist, J., Horváth, G., Hultborn, R., Jacobsson, L., Jensen, H. J., Karlsson, B., Lindegren, S., & Palm, S. (2003) · PubMed · Cited by 50 · see citing works

OEDIPE: A Personalized Dosimetric Tool Associating Voxel-Based Models with MCNPX

Chiavassa, S., Bardiès, M., Guiraud-Vitaux, F., Bruel, D., Jourdain, J.-R., Franck, D., & Aubineau-Lanièce, I. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.325 · Cited by 50 · see citing works

The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer

Willhauck, M. J., Samani, B. R. S., Wolf, I., Senekowitsch–Schmidtke, R., Stark, H., Meyer, G.-J., Knapp, W. H., Göke, B., Morris, J. C., & Spitzweg, C. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0775-4 · Cited by 50 · see citing works

Radioimmunotherapy of Human Colon Carcinoma Xenografts Using a 213 Bi-Labeled Domain-Deleted Humanized Monoclonal Antibody

Milenic, D. E., Garmestani, K., Dadachova, E., Chappell, L. L., Albert, P. S., Hill, D., Schlom, J., & Brechbiel, M. W. (2004) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497804323071904 · Cited by 50 · see citing works

Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.

Henriksen, G., Bruland, Ø. S., & Larsen, R. H. (2004) · PubMed · Cited by 50 · see citing works

The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia

Ruble, G., Wu, C., Squire, R. A., Gansow, O. A., & Strand, M. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)02119-1 · Cited by 49 · see citing works

Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer

Castello, A., Macapinlac, H. A., Lopci, E., & Santos, E. B. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4051-y · Cited by 49 · see citing works

Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.

Andersson, H., Palm, S., Lindegren, S., Bäck, T. A., Jacobsson, L., Leser, G., & Horváth, G. (2001) · PubMed · Cited by 48 · see citing works

Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice

Dizdarevic, S., Petersen, R. H., Essler, M., Versari, A., Bourre, J. C., la Fougère, C. J., Valdagni, R., Paganelli, G., Ezziddin, S., Kalinovský, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-4261-y · Cited by 48 · see citing works

LnPO 4 Nanoparticles Doped with Ac-225 and Sequestered Daughters for Targeted Alpha Therapy

McLaughlin, M. F., Robertson, D., Pevsner, P. H., Wall, J. S., Mirzadeh, S., & Kennel, S. J. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1546 · Cited by 47 · see citing works

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer

Knör, S., Sato, S., Huber, T., Morgenstern, A., Bruchertseifer, F., Schmitt, M., Kessler, H., Senekowitsch–Schmidtke, R., Magdolen, V., & Seidl, C. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0582-3 · Cited by 47 · see citing works

Antibody–drug conjugates come of age in oncology

Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 858 · see citing works

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

Eychenne, R., Chérel, M., Haddad, F., Guérard, F., & Gestin, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060906 · Cited by 201 · see citing works

Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets

Wang, Y., Zhang, Z., Sun, W., Zhang, J., Xu, Q., Zhou, X., & Mao, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113524 · Cited by 141 · see citing works

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy

Eychenne, R., Bouvry, C., Bourgeois, M., Loyer, P., Benoist, É., & Lepareur, N. (2020) · Molecules · doi:10.3390/molecules25174012 · Cited by 125 · see citing works

Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives

Hooijman, E. L., Radchenko, V., Ling, S. W., Konijnenberg, M., Brabander, T., Koolen, S. L. W., & de Blois, E. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00239-1 · Cited by 88 · see citing works

Roles of Podoplanin in Malignant Progression of Tumor

Suzuki, H., Kaneko, M. K., & Kato, Y. (2022) · Cells · doi:10.3390/cells11030575 · Cited by 85 · see citing works

Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis

Satapathy, S., Sood, A. K., Das, C. K., & Mittal, B. R. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00349-w · Cited by 73 · see citing works

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works

Radiotheranostic landscape: A review of clinical and preclinical development

Tran, H. H., Yamaguchi, A., & Manning, H. C. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07103-7 · Cited by 67 · see citing works

Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy

Bidkar, A. P., Wang, S., Bobba, K. N., Chan, E., Bidlingmaier, S. M., Egusa, E. A., Peter, R., Ali, U., Meher, N., Wadhwa, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3291 · Cited by 56 · see citing works

Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review

Patell, K., Kurian, M., Garcia, J. A., Mendiratta, P., Barata, P. C., Jia, A. Y., Spratt, D. E., & Brown, J. R. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2213892 · Cited by 54 · see citing works

Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses

Cheal, S. M., McDevitt, M. R., Santich, B. H., Patel, M., Yang, G., Fung, E. K., Veach, D. R., Bell, M. M., Ahad, A., Vargas, D. B., et al. (2020) · Theranostics · doi:10.7150/thno.48810 · Cited by 49 · see citing works

Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms.

Tafreshi, N. K., Pandya, D. N., Tichacek, C. J., Budzevich, M. M., Wang, Z., Reff, J. N., Engelman, R. W., Boulware, D. C., Chiappori, A. A., Strosberg, J. R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05315-1 · Cited by 50 · see citing works

Biomarkers of Genotoxicity in Medical Workers Exposed to Low-Dose Ionizing Radiation: Systematic Review and Meta-Analyses

Baudin, C., Bernier, M., Klokov, D. Y., & Andreassi, M. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147504 · Cited by 51 · see citing works

How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy

Burkett, B. J., Dundar, A., Young, J. R., Packard, A. T., Johnson, G. B., Halfdanarson, T. R., Eiring, R. A., Gansen, D. N., Patton, C. M., & Kendi, A. T. (2020) · Radiology · doi:10.1148/radiol.2020201745 · Cited by 43 · see citing works

Why bother with alpha particles?

King, A. P., Lin, F. I., & Escorcia, F. E. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05431-y · Cited by 40 · see citing works

Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

Batra, V., Samanta, M., Makvandi, M., Groff, D., Martorano, P., Elias, J., Ranieri, P., Tsang, M., Hou, C., Li, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0400 · Cited by 37 · see citing works

Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome

Leung, K., Schaefer, K., Lin, Z., Yao, Z. W., & Wells, J. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00554 · Cited by 39 · see citing works

Lipophilicity Determines Routes of Uptake and Clearance, and Toxicity of an Alpha-Particle-Emitting Peptide Receptor Radiotherapy

Tafreshi, N. K., Kil, H., Pandya, D. N., Tichacek, C. J., Doligalski, M. L., Budzevich, M. M., Delva, N. C., Langsen, M., Vallas, J. A., Boulware, D. C., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00035 · Cited by 38 · see citing works

Targeted thorium-227 conjugates as treatment options in oncology

Karlsson, J., Schatz, C. A., Wengner, A. M., Hammer, S., Scholz, A., Cuthbertson, A., Wagner, V. J., Hennekes, H., Jardine, V., & Hagemann, U. B. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1071086 · Cited by 32 · see citing works

FZD10‐targeted α‐radioimmunotherapy with 225Ac‐labeled OTSA101 achieves complete remission in a synovial sarcoma model

Sudo, H., Tsuji, A. B., Sugyo, A., Harada, Y., Nagayama, S., Katagiri, T., Nakamura, Y., & Higashi, T. (2021) · Cancer Science · doi:10.1111/cas.15235 · Cited by 30 · see citing works

A Projection-Domain Low-Count Quantitative SPECT Method for ɑ-Particle-Emitting Radiopharmaceutical Therapy

Li, Z., Benabdallah, N., Abou, D. S., Baumann, B. C., Dehdashti, F., Ballard, D. H., Liu, J., Jammalamadaka, U. M., Laforest, R. A., Wahl, R. L., et al. (2022) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2022.3175435 · Cited by 28 · see citing works

Theoretical Study of Actinide(III)-DOTA Complexes

Kovács, A. (2021) · ACS Omega · doi:10.1021/acsomega.1c01292 · Cited by 25 · see citing works

Structure and properties of DOTA-chelated radiopharmaceuticals within the 225 Ac decay pathway

Khabibullin, A. R., Karolak, A. M., Budzevich, M. M., McLaughlin, M. L., Morse, D. L., & Woods, L. M. (2018) · MedChemComm · doi:10.1039/c8md00170g · Cited by 23 · see citing works

Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer

Birindelli, G., Drobnjaković, M., Morath, V., Steiger, K., D’Alessandria, C., Gourni, E., Afshar‐Oromieh, A., Weber, W., Rominger, A., Eiber, M., et al. (2021) · Cancers · doi:10.3390/cancers13143429 · Cited by 23 · see citing works

Development of 225Ac-doped biocompatible nanoparticles for targeted alpha therapy

Toro-González, M., Akingbesote, N. D., Bible, A. N., Pal, D., Sanders, B., Ivanov, A. S., Jansone‐Popova, S., Popovs, I., Benny, P. D., Perry, R. J., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02520-6 · Cited by 22 · see citing works

Treatment with Radiopharmaceuticals and Radionuclides in Breast Cancer: Current Options

Altıparmak, B., & Yurt, F. (2021) · European Journal of Breast Health · doi:10.4274/ejbh.galenos.2021.2021-3-4 · Cited by 22 · see citing works

Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach

Vi, C., Mandarano, G., & Shigdar, S. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116163 · Cited by 25 · see citing works

Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma

Sudo, H., Tsuji, A. B., Sugyo, A., Kaneko, M. K., Kato, Y., Nagatsu, K., Suzuki, H., & Higashi, T. (2021) · Cells · doi:10.3390/cells10102503 · Cited by 22 · see citing works

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

Handula, M., Beekman, S., Konijnenberg, M., Stuurman, D. C., de Ridder, C., Bruchertseifer, F., Morgenstern, A., Denkova, A. G., de Blois, E., & Seimbille, Y. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00197-0 · Cited by 21 · see citing works

Applications of Yttrium-90 (90Y) in Hepatocellular Carcinoma

Jiang, Z., Yang, F., & Wang, W. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s445898 · Cited by 20 · see citing works

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts

Nishri, Y., Vatarescu, M., Luz, I., Epstein, L., Dumančić, M., Mare, S. D., Shai, A., Schmidt, M. T., Deutsch, L., Den, R. B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888100 · Cited by 19 · see citing works

Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting

Verona, M., Rubagotti, S., Croci, S., Sarpaki, S., Borgna, F., Tosato, M., Vettorato, E., Marzaro, G., Mastrotto, F., & Asti, M. (2021) · Molecules · doi:10.3390/molecules26040918 · Cited by 18 · see citing works

ICRP Publication 153: Radiological Protection in Veterinary Practice

(2022) · Annals of the ICRP · doi:10.1177/01466453221142702 · Cited by 17 · see citing works

Estimating the Relative Biological Effectiveness of Auger Electron Emitter 123I in Human Lymphocytes

Fourie, H., Nair, S., Miles, X., Rossouw, D. D., Beukes, P., Newman, R. T., Zeevaart, J. R., Vandevoorde, C., & Slabbert, J. P. (2020) · Frontiers in Physics · doi:10.3389/fphy.2020.567732 · Cited by 17 · see citing works

Compton and Proximity Imaging of Ac In Vivo With a CZT Gamma Camera: A Proof of Principle With Simulations

Rodríguez, J. C., Huh, Y., Gullberg, G. T., & Seo, Y. (2022) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2022.3166116 · Cited by 19 · see citing works

Selection of radionuclide(s) for targeted alpha therapy based on their nuclear decay properties

Ree, S. M., Greenwood, H., Young, J. D., Roberts, R., Livens, F. R., Heath, S. L., & Sosabowski, J. K. (2024) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001832 · Cited by 16 · see citing works

Response to RL‐225Ac in prostate cancer: Effect of prior treatment with RL‐177Lu: A systematic review of the literature

Stangl‐Kremser, J., Ricaurte‐Fajardo, A., Subramanian, K., Osborne, J. R., Sun, M., Tagawa, S. T., & Bander, N. H. (2023) · The Prostate · doi:10.1002/pros.24531 · Cited by 16 · see citing works

Preclinical investigation of [149Tb]Tb-DOTATATE and [149Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy

Mapanao, A. K., Busslinger, S. D., Mehta, A., Kegler, K., Favaretto, C., Grundler, P. V., Talip, Z., Köster, U., Johnston, K., Schibli, R., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07035-8 · Cited by 16 · see citing works

Review of current status of targeted alpha therapy in cancer treatment

Jabbar, T., Bashir, S., & Babar, M. (2023) · Nuclear Medicine Review · doi:10.5603/nmr.2023.0003 · Cited by 15 · see citing works

Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225

Castillo, D., Saint‐Hubert, M. D., Crabbé, M., Struelens, L., & Koole, M. J. B. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03266-5 · Cited by 15 · see citing works

225Ac-rHDL Nanoparticles: A Potential Agent for Targeted Alpha-Particle Therapy of Tumors Overexpressing SR-BI Proteins

Hernández-Jiménez, T., Ferro‐Flores, G., Morales-Ávila, E., Isaac‐Olivé, K., Ocampo‐García, B., Aranda‐Lara, L., Santos‐Cuevas, C., Luna‐Gutiérrez, M., Nardo, L. D., Rosato, A., et al. (2022) · Molecules · doi:10.3390/molecules27072156 · Cited by 15 · see citing works

Alpha Before Beta: Exceptional Response to First-Line 225Ac-DOTATATE in a Patient of Metastatic Neuroendocrine Tumor With Extensive Skeletal Involvement.

Satapathy, S., Sood, A., Das, C. K., Kavanal, A. J., & Mittal, B. R. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003823 · Cited by 14 · see citing works

Radiation dosimetry in medicine using II-VI semiconductors

Damulira, E. (2022) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2022.06.001 · Cited by 14 · see citing works

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab

Roy, J., Jagoda, E. M., Basuli, F., Vasalatiy, O. V., Phelps, T. E., Wong, K. J., Ton, A., Hagemann, U. B., Cuthbertson, A., Cole, P. E., et al. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4492 · Cited by 14 · see citing works

A multifunctional 64+67Cu-pyrazolone complex: Green synthesis, radiolabeling, molecular docking, and tumor-targeted theranostic evaluation

Shamsel‐Din, H. A., Abdou, M. M., elsayed, D. A., & Gizawy, M. A. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103971 · Cited by 13 · see citing works

The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How?

Frantellizzi, V., Ricci, M., Cimini, A., Filippi, L., Conte, M., Feo, M. S. D., & Vincentis, G. D. (2023) · Applied Sciences · doi:10.3390/app13031890 · Cited by 13 · see citing works

Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics

Kauffman, N., Morrison, J., O’Brien, K., Fan, J., & Zinn, K. R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041138 · Cited by 13 · see citing works

Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?

Kleynhans, J., Ebenhan, T., Cleeren, F., & Sathekge, M. M. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06719-5 · Cited by 13 · see citing works

Covalent core-radiolabeling of polymeric micelles with 125I/211At for theranostic radiotherapy

Sporer, E., Poulie, C. B. M., Bäck, T. A., Lindegren, S., Jensen, H. J., Kempen, P. J., Kjær, A., Herth, M. M., & Jensen, A. I. (2022) · Nanotheranostics · doi:10.7150/ntno.71906 · Cited by 13 · see citing works

The low‐LET radiation contribution to the tumor dose in diffusing alpha‐emitters radiation therapy

Epstein, L., Heger, G., Roy, A., Gannot, I., Kelson, I., & Arazi, L. (2023) · Medical Physics · doi:10.1002/mp.16885 · Cited by 13 · see citing works

Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects

Nawar, M. F., Selim, A. A., Essa, B. M., El-Daoushy, A. F., Swidan, M. M., Chambers, C., Al-Qahtani, M. H., Smith, C. J., & Sakr, T. M. (2025) · Cancers · doi:10.3390/cancers17183055 · Cited by 12 · see citing works

Metal–ligand interactions in complexes of cyclen-based ligands with Bi and Ac

Kovács, A., & Varga, Z. (2021) · Structural Chemistry · doi:10.1007/s11224-021-01816-9 · Cited by 12 · see citing works

Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy

Cruz-Nova, P., Trujillo-Nolasco, M., Aranda‐Lara, L., Ferro‐Flores, G., & Ocampo-García, B. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109044 · Cited by 12 · see citing works

Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases

Patel, C. M., Wadas, T. J., & Shiozawa, Y. (2021) · Molecules · doi:10.3390/molecules26082162 · Cited by 11 · see citing works

Core–shell structured gold nanoparticles as carrier for 166Dy/166Ho in vivo generator

Wang, R., Ponsard, B., Wolterbeek, H. T., & Denkova, A. G. (2022) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-022-00170-3 · Cited by 11 · see citing works

Effective therapy with Bismuth-212 labeled macroaggregated albumin in orthotopic mouse breast tumor models

Kauffman, N., Singh, S. K., Morrison, J., & Zinn, K. R. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1204872 · Cited by 10 · see citing works

Investigation of dosimetric characteristics of radiochromic film in response to alpha particles emitted from Americium‐241

Martínez, V. D. D., Cyr, M., Dević, S., Tomic, N., Lewis, D. F., & Enger, S. A. (2024) · Medical Physics · doi:10.1002/mp.17133 · Cited by 9 · see citing works

Cancer-targeting drug conjugates drives a new era in precise cancer treatment

Deng, J., Shi, J., Li, D., Jiao, X., Liu, J., Tian, H., Liu, N., Luo, C., Kamei, K., & Tian, C. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.110960 · Cited by 9 · see citing works

An Anti-EGFR Antibody–Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer

Tikum, A. F., Henning, N. W., Ketchemen, J. P., Doroudi, A., Babeker, H., Njotu, F. N., Nwangele, E., Monzer, A., Gray, B. M., Torlakovic, E., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2266 · Cited by 9 · see citing works

First measurements of radon‐220 diffusion in mice tumors, towards treatment planning in diffusing alpha‐emitters radiation therapy

Heger, G., Dumančić, M., Luz, I., Vatarescu, M., Weizman, N., Miller, B. W., Cooks, T., & Arazi, L. (2024) · Medical Physics · doi:10.1002/mp.17020 · Cited by 9 · see citing works

Joint Regional Uptake Quantification of Thorium-227 and Radium-223 Using a Multiple-Energy-Window Projection-Domain Quantitative SPECT Method

Li, Z., Benabdallah, N., Laforest, R. A., Wahl, R. L., Thorek, D. L. J., & Jha, A. K. (2024) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2024.3420228 · Cited by 9 · see citing works

Tailoring the Radionuclide Encapsulation and Surface Chemistry of La(223Ra)VO4 Nanoparticles for Targeted Alpha Therapy

Toro-González, M., Peacock, A., Miskowiec, A., Cullen, D. A., Copping, R., Mirzadeh, S., & Davern, S. M. (2021) · Journal of Nanotheranostics · doi:10.3390/jnt2010003 · Cited by 9 · see citing works

ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for223Ra-Based Radiopharmaceutical Therapies

Li, Z., Benabdallah, N., Luo, J. R., Wahl, R. L., Thorek, D. L. J., & Jha, A. K. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266719 · Cited by 8 · see citing works

Narrative review of the role of yttrium-90 selective internal radiation therapy in the surgical management of colorectal liver metastases

Moslim, M. A., & Jeyarajah, D. R. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-96 · Cited by 8 · see citing works

Head‐to‐head comparison of three chelates reveals DOTAGA promising for 225Ac labeling of anti‐FZD10 antibody OTSA101

Sudo, H., Tsuji, A. B., Sugyo, A., Harada, Y., Nagayama, S., Katagiri, T., Nakamura, Y., & Higashi, T. (2023) · Cancer Science · doi:10.1111/cas.15978 · Cited by 7 · see citing works

Production and Quality Control of Actinium-225 Radiopharmaceuticals

INTERNATIONAL ATOMIC ENERGY AGENCY (2024) · International Atomic Energy Agency eBooks · doi:10.61092/iaea.95h3-2ji2 · Cited by 7 · see citing works

Metal-ligand bonding in bispidine chelate complexes for radiopharmaceutical applications

Kovács, A. (2022) · Structural Chemistry · doi:10.1007/s11224-022-01902-6 · Cited by 7 · see citing works

Enhancing the Therapeutic Effect of 2-211At-astato-α-methyl-L-phenylalanine with Probenecid Loading

Hanaoka, H., Ohshima, Y., Suzuki, H. Y., Sasaki, I., Watabe, T., Ooe, K., Watanabe, S., & Ishioka, N. S. (2021) · Cancers · doi:10.3390/cancers13215514 · Cited by 6 · see citing works

Theoretical Study of Complexes of Tetravalent Actinides with DOTA

Kovács, A. (2022) · Symmetry · doi:10.3390/sym14112451 · Cited by 6 · see citing works

A list-mode multi-energy window low-count SPECT reconstruction method for isotopes with multiple emission peaks

Rahman, M. A., Li, Z., Yu, Z., Laforest, R. A., Thorek, D. L. J., & Jha, A. K. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00558-3 · Cited by 6 · see citing works

Monte Carlo simulations for targeted beta therapy: An optimization for liver lesions and comparison of dose distributions in other organs

Kara, A., & Mammadzada, E. (2023) · Radiation Medicine and Protection · doi:10.1016/j.radmp.2023.11.001 · Cited by 6 · see citing works

Growth hormone and radiation therapy: friend, foe, or both?

Bahamondes, V., & Wu, S. (2024) · Endocrine Related Cancer · doi:10.1530/erc-22-0371 · Cited by 6 · see citing works

Radiological and Molecular Analysis of Radioiodinated Anastrozole and Epirubicin as Innovative Radiopharmaceuticals Targeting Methylenetetrahydrofolate Dehydrogenase 2 in Solid Tumors

Binmujlli, M. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050616 · Cited by 6 · see citing works

Radiopharmaceutical: An Update and Comparison of Preclinical Investigation Result of Alpha and Beta Emitter Radioisotope

Luhung, A., Hasanah, A. N., & Ramdhani, D. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s570831 · Cited by 5 · see citing works

Health and environmental risk of alpha emitter radium

Verma, D. K., Rameshwari, R., & Meena, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95235-4.00015-3 · Cited by 5 · see citing works

Cryo-electron microscopy reveals a single domain antibody with a unique binding epitope on fibroblast activation protein alpha

Xu, Z., Sinha, A., Pandya, D. N., Schnicker, N. J., & Wadas, T. J. (2025) · RSC Chemical Biology · doi:10.1039/d4cb00267a · Cited by 5 · see citing works

Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands

Redfern, J. S. (2020) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2020.08.00313 · Cited by 5 · see citing works

Mathematical Modeling of In Vivo Alpha Particle Generators and Chelator Stability

Zaid, N. R. R., Kletting, P., Beer, A. J., Stallons, T. A. R., Torgue, J. J.-C., & Glatting, G. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4112 · Cited by 5 · see citing works

EANM recommendations for dosimetry in targeted radionuclide therapy with alpha-emitters

Gabiña, P. M., Gleisner, K. S., Chouin, N., Tran‐Gia, J., Koole, M., Cremonesi, M., Denis-Bacelar, A. M., Cassano, B., Verburg, F. A., Brosch-Lenz, J., et al. (2026) · EANM Innovation · doi:10.1016/j.eanmi.2025.100018 · Cited by 5 · see citing works

The sodium iodide symporter (NIS) as theranostic gene: potential role in pre-clinical therapy of extra-thyroidal malignancies

Darabi, N., Keshavarz, M., Nabipour, I., & Assadi, M. (2023) · Clinical and Translational Imaging · doi:10.1007/s40336-023-00540-0 · Cited by 4 · see citing works

Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment

Satapathy, S., Chandekar, K. R., & Bal, C. S. (2023) · PET Clinics · doi:10.1016/j.cpet.2022.11.004 · Cited by 4 · see citing works

A Technique to Quantify Very Low Activities in Regions of Interest With a Collimatorless Detector

Rodríguez, J. C., Bobba, K. N., Du, S., Peter, R., Gullberg, G. T., Bidkar, A. P., Flavell, R. R., & Seo, Y. (2024) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2024.3377142 · Cited by 4 · see citing works

Detailed Chemistry Studies of 225Actinium Labeled Radiopharmaceuticals

Kılbaş, B., & Eryilmaz, K. (2021) · Current Radiopharmaceuticals · doi:10.2174/1874471014666210528123936 · Cited by 4 · see citing works

Characterization of MOSFET Dosimeters for Alpha Particle Therapy

Su, F.-Y., Biasi, G., Tran, L. T., Pan, V. A., Hill, D., Lielkajis, M., Cutajar, D. L., Petasecca, M., Lerch, M., Pastuović, Ž., et al. (2022) · IEEE Transactions on Nuclear Science · doi:10.1109/tns.2022.3153697 · Cited by 4 · see citing works

Theoretical study of heptadentate bispidine ligands for radiopharmaceutic applications

Kovács, A. (2022) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2022.113716 · Cited by 4 · see citing works

Bone Marrow Relative Biological Effectiveness for a 212Pb-labeled Anti-HER2/neu Antibody

Liatsou, I., Josefsson, A., Yu, J., Cortez, A. G., Bastiaannet, R., Velarde, E., Davis, K. U., Brayton, C. F., Wang, H., Torgue, J. J.-C., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.1842 · Cited by 4 · see citing works

Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma

Tsuji, S., & Imai, K. (2023) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.99.003 · Cited by 4 · see citing works

In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy.

Birindelli, G., Drobnjaković, M., Morath, V., Steiger, K., D’Alessandria, C., Gourni, E., Afshar‐Oromieh, A., Weber, W., Rominger, A., Eiber, M., et al. (2021) · doi:10.48350/162500 · Cited by 4 · see citing works

PARP1-targeted alpha therapy enhances target expression

Babazada, H., Martorano, P., Lee, H. S., Geng, S., Batra, V., Maris, J. M., Pryma, D. A., Gitto, S. B., & Farwell, M. D. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01256-0 · Cited by 3 · see citing works

Diffusing alpha‐emitters radiation therapy: In vivo measurements of effective diffusion and clearance rates across multiple tumor types

Dumančić, M., Heger, G., Luz, I., Vatarescu, M., Weizman, N., Epstein, L., Cooks, T., & Arazi, L. (2025) · Medical Physics · doi:10.1002/mp.70052 · Cited by 3 · see citing works

Enhanced Radionuclide Therapy via the Conjugation of Pentadecanoic Acids With 225 Ac ‐ and 177 Lu ‐Labeled RGD Peptides

Yoshimoto, M., Wada, S., Yoshii, Y., Hanadate, S., Inaki, A., & Fujii, H. (2025) · Cancer Science · doi:10.1111/cas.70222 · Cited by 3 · see citing works

Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors

Shoshan, Y., Gomori, M. J., Moss, L., Bari, S. E., Edery, N., Den, R. B., Arazi, L., Popovtzer, A., Feldman, J., & Moscovici, S. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04919-5 · Cited by 3 · see citing works

Physics and small‐scale dosimetry of α$\alpha$‐emitters for targeted radionuclide therapy: The case of 211At$^{211}{\rm At}$

Alcocer‐Ávila, M., Larouze, A., Groetz, J., Hindié, E., & Champion, C. (2024) · Medical Physics · doi:10.1002/mp.17016 · Cited by 3 · see citing works

WIN-PDQ: a Wiener-estimator-based projection-domain quantitative SPECT method that accounts for intra-regional uptake heterogeneity

Li, Z., Benabdallah, N., Thorek, D. L. J., & Jha, A. K. (2024) · SPIE Medical Imaging: Physics of Medical Imaging · doi:10.1117/12.3006569 · Cited by 3 · see citing works

Precision Atomistic Structures of Actinium-/Radium-/Barium-Doped Lanthanide Nanoconstructs for Radiotherapeutic Applications

Goswami, M., Toro-González, M., Moon, J., & Davern, S. M. (2024) · ACS Nano · doi:10.1021/acsnano.3c13213 · Cited by 3 · see citing works

Advances and Perspectives on Bioelectronic and Atomic Nanogenerators for Anticancer Therapy

Mariello, M. (2025) · Nanoenergy Advances · doi:10.3390/nanoenergyadv5020004 · Cited by 3 · see citing works

Radioligand Theranostics in the Management of Neuroendocrine Tumors

Harris, A. G., Vinik, A. I., O’Dorisio, T. M., & O'Dorisio, M. S. (2020) · Pancreas · doi:10.1097/mpa.0000000000001546 · Cited by 3 · see citing works

Metallobiochemistry of ultratrace levels of bismuth in the rat I. Metabolic patterns of 205+206Bi3+ in the blood

Sabbioni, E., Groppi, F., Gioacchino, M. D., Petrarca, C., & Manenti, S. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126760 · Cited by 3 · see citing works

Molecular and Functional Imaging and Theranostics of the Tumor Microenvironment

Penet, M., Kakkad, S. M., Pacheco‐Torres, J., Bharti, S. K., Krishnamachary, B., & Bhujwalla, Z. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00069-7 · Cited by 3 · see citing works

An overview of targeted alpha therapy

Kim, Y., & Brechbiel, M. W. (2011) · Tumor Biology · doi:10.1007/s13277-011-0286-y · Cited by 280 · see citing works

The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond

Elgqvist, J., Frost, S. H. L., Pouget, J., & Albertsson, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2013.00324 · Cited by 194 · see citing works

Targeted Alpha Therapy in Cancer Management: Therapeutic Prospects of Nuclear Medicine in Oncology

Mdanda, S., Mdlophane, A. H., Ndlovu, H., Ramonaheng, K., Qebetu, M., Mahapane, J., Kgatle, M., Mzizi, Y. V., Sebatana, R., Cele, Z. E. D., et al. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_195 · Cited by 2 · see citing works

Bringing atoms to bedside with targeted alpha therapy

Selvam, A., & Green, B. D. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00782-8 · Cited by 3 · see citing works

The next generation of radioimmunotherapy: Targeted alpha therapy (TAT)

Molnar, I., Burak, E. S., Forbes, J., Simms, R. W., & Valliant, J. F. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy046.020 · Cited by 2 · see citing works